8-K: Monogram Technologies Merger Faces HSR Review Extension

Monogram Technologies and Zimmer Biomet extended their merger regulatory review by withdrawing and refiling HSR notifications, pushing the waiting period to October 6, 2025.

Summary

• Monogram Technologies Inc. and Zimmer Biomet Holdings, Inc. are proceeding with their previously announced merger.
• On September 4, 2025, Zimmer Biomet voluntarily withdrew and immediately resubmitted its pre-merger Notification and Report Form under the Hart-Scott-Rodino (HSR) Act.
• This action provides the Federal Trade Commission (FTC) with additional time for review.
• A new 30-day HSR waiting period commenced, set to expire on October 6, 2025, at 11:59 p.m., Eastern Time, unless terminated earlier or extended.
• Both companies continue to work constructively with the FTC and still expect to consummate the merger in the second half of 2025.
• The merger remains subject to regulatory approvals, Monogram shareholder adoption, and other customary closing conditions.

Sentiment

Score: 6

Explanation: The filing indicates a procedural delay in regulatory approval for the merger, which is a slight negative. However, management explicitly states this is a 'standard procedure' and reiterates the expectation to close in the second half of 2025, mitigating significant negative sentiment. The continued commitment to the merger is a positive, but the extended review adds a minor layer of uncertainty.

Positives

• Companies continue to work constructively with the FTC, indicating ongoing commitment to the merger.
• The expectation to consummate the merger in the second half of 2025 remains unchanged, despite the HSR process extension.
• Withdrawing and refiling HSR notifications is described as a "standard procedure" for antitrust review, suggesting it is not an unusual or necessarily negative development.

Negatives

• The HSR review period has been extended, indicating that the FTC requires more time for its antitrust assessment.
• The extension introduces a slight delay in the regulatory approval timeline, pushing the HSR waiting period expiration to October 6, 2025.

Risks

• Failure to satisfy conditions to closing the Merger, including obtaining necessary regulatory approvals in the anticipated timeframe or at all.
• Uncertainties regarding whether Monogram stockholders will approve the Merger.
• Possibility that the Merger does not close.
• Risk of competing offers or acquisition proposals for Monogram.
• Occurrence of any event, change, or circumstances that could lead to the termination of the Merger Agreement, potentially requiring Monogram to pay a termination fee.
• Risks related to the ability to realize the anticipated benefits of the Merger, including the possibility that expected benefits will not be realized or not within the expected time period.
• Risk that the businesses will not be integrated successfully.
• Risks relating to changing demand for Monogram's existing products.
• Risks relating to the achievement of revenue and other milestones necessary for the payment of any contingent value rights.
• Disruption from the Merger making it more difficult to maintain business and operational relationships with customers, vendors, service providers, and sales representatives.
• Inability to attract, motivate, or retain key executives, employees, and other associates.
• Risks related to the Merger diverting Monogram's management's attention from ongoing business operations.
• Negative effects of the announcement or consummation of the Merger on the market price of Monogram common stock and on Monogram's operating results.
• Significant transaction costs associated with the Merger.
• Unknown liabilities that may arise from the Merger.
• Risk of litigation, including stockholder litigation, and/or regulatory actions, including any conditions, limitations, or restrictions placed on approvals by governmental entities related to the Merger.
• Other risks and uncertainties discussed in Monogram's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q, and the definitive proxy statement relating to the Merger.

Future Outlook

Monogram Technologies and Zimmer Biomet continue to expect the merger to be consummated in the second half of 2025, subject to regulatory approvals, Monogram shareholder adoption, and other customary closing conditions. The voluntary withdrawal and refiling of HSR notifications is described as a standard procedure to allow additional time for antitrust review.

Management Comments

• "Withdrawing and refiling pre-merger notifications is a standard procedure in order to provide additional time for antitrust review of certain transactions."
• "The Company and Zimmer Biomet continue to work constructively with FTC staff in the FTCs review of the Merger and continue to expect to consummate the Merger in the second half of 2025."

Industry Context

The medical device and healthcare technology sectors are subject to rigorous antitrust scrutiny, especially for significant mergers. Regulatory bodies like the FTC often require extensive review periods to ensure competitive markets. The voluntary withdrawal and refiling of HSR notifications is a common tactic used by companies to manage these extended review processes without triggering a "second request," which would entail a much longer and more burdensome investigation. This indicates the FTC is taking a close look at the competitive implications of the Monogram-Zimmer Biomet merger within its specific market segments.

Comparison to Industry Standards

• The voluntary withdrawal and refiling of HSR notifications is a recognized strategy in large-scale mergers, particularly in industries with high regulatory oversight like healthcare, to provide antitrust authorities (e.g., FTC, DOJ) more time for review without initiating a formal "second request" which can significantly prolong the process.
• For example, similar procedures have been observed in other major healthcare acquisitions, such as when CVS Health acquired Aetna or when AbbVie acquired Allergan, where companies proactively engaged with regulators to manage the review timeline.
• The continued expectation of closing in the second half of 2025, despite the HSR extension, aligns with typical merger timelines where regulatory hurdles are anticipated and often managed through such procedural steps.

Legal Proceedings

• Risk of litigation, including stockholder litigation, related to the Merger.
• Risk of regulatory actions, including any conditions, limitations, or restrictions placed on approvals by any applicable governmental entities related to the Merger.

Stakeholder Impact

• Shareholders: Potential impact on stock price due to merger news and regulatory delays; requirement to vote on the Merger Agreement; potential for contingent value rights if applicable milestones are met.
• Employees: Potential disruption from the Merger making it more difficult to maintain business and operational relationships; risks related to attracting, motivating, or retaining key executives and employees.
• Customers, Vendors, Service Providers, Sales Representatives: Potential disruption from the Merger making it more difficult to maintain business and operational relationships.
• Regulators (FTC): Engaged in an extended review process to ensure antitrust compliance.

Next Steps

• Continued constructive engagement with FTC staff regarding the merger review.
• Expiration of the new 30-day HSR waiting period on October 6, 2025, unless terminated earlier or extended.
• Monogram shareholders to vote on the adoption of the Merger Agreement.
• Satisfaction or waiver of other customary closing conditions for the merger.
• Consummation of the Merger, expected in the second half of 2025.

Key Dates

Recommendation

The filing indicates a procedural delay in the merger's regulatory approval, which introduces a minor element of uncertainty. While management characterizes this as a "standard procedure" and reiterates the expectation for a second-half 2025 close, the extended FTC review suggests a closer look at the transaction. For investors, this update doesn't fundamentally alter the merger's prospects but adds a slight, albeit common, hurdle. A "hold" recommendation is appropriate as the core thesis of the acquisition remains, but the extended regulatory timeline warrants continued monitoring rather than immediate buying or selling based solely on this procedural update. The risks associated with regulatory approval, potential termination, and integration remain pertinent.

Keywords

Monogram Technologies, Zimmer Biomet, Merger, Acquisition, HSR Act, Antitrust Review, SEC Filing, MGRM, Regulatory Approval, Corporate Governance